International Stabilization Force for Gaza Nears Deployment as U.S.-Led Planning Advances 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Judge Orders Return of Seized Evidence in Comey-Related Case, DOJ May Seek New Warrant 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Trump Signals Conditional Push for Ukraine Peace Talks as Frustration Mounts 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Bolivia Orders Pre-Trial Detention of Former President Luis Arce Over Embezzlement Probe 
Modi and Trump Hold Phone Call as India Seeks Relief From U.S. Tariffs Over Russian Oil Trade 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Democrats Face Uphill Battle in Midterm Elections Despite Recent Victories, Reuters/Ipsos Poll Shows 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
U.S. Lifts Sanctions on Brazilian Supreme Court Justice Amid Shift in Brazil Relations 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 
Trump Signs Executive Order to Establish National AI Regulation Standard 
New Epstein Photos Surface Showing Trump as Lawmakers Near Document Release Deadline 
A panel of independent U.S. vaccine experts has announced plans to review the long-standing recommendation for administering the hepatitis B vaccine at birth. The Vaccine Integrity Project, an organization focused on ensuring vaccine safety and efficacy, said it expects to complete its review by early December. The move follows a decision by a federal advisory committee under the Centers for Disease Control and Prevention (CDC) to delay a vote on whether to postpone the first hepatitis B dose for newborns of mothers who test negative for the virus.
The review will analyze decades of scientific research on the safety, effectiveness, and public health outcomes of administering the hepatitis B vaccine within the first 24 hours of life. It will also evaluate the potential risks of delaying the vaccine, including missed opportunities for immunization due to incomplete maternal screening or lack of follow-up.
Currently, the CDC and World Health Organization recommend that all newborns receive the hepatitis B vaccine shortly after birth to prevent mother-to-child transmission. Data show that infants infected at birth or within their first year face up to a 90% chance of developing chronic hepatitis B, which can lead to cirrhosis or liver cancer later in life.
The discussion has gained political attention after President Donald Trump questioned the necessity of giving the vaccine at birth, suggesting instead that it could be delayed until age 12, citing its transmission through sexual contact. However, health experts emphasize that perinatal infection remains a significant transmission route.
Since the introduction of widespread vaccination, hepatitis B infection rates in the United States have dropped by nearly 90%, from about 9.6 per 100,000 people before the vaccine program began to around one per 100,000 in 2018. Currently, six hepatitis vaccines are approved for use in the U.S., continuing to play a vital role in reducing the disease’s prevalence and protecting future generations.
